As fall respiratory virus season approaches alongside rising COVID-19 numbers, public health experts emphasize that updated vaccines and lesser-known treatments like monoclonal antibodies remain critical tools for vulnerable populations. According to Your Local Epidemiologist, COVID-19 continues to spread exponentially across all regions of the country, with the West and South states leading the pack even as overall baseline levels remain relatively low compared to previous waves.
Updated COVID-19 Vaccines and Common Cold Peaks
The FDA licensed the Covid-19 vaccine last week, triggering physical mailing and distribution to clinics, hospitals, and pharmacies, according to Your Local Epidemiologist. Officials expect the updated shots to be available in the next two weeks. Meanwhile, common cold rates are climbing as school-aged children’s petri dishes mix daily, with common colds typically peaking at the end of September based on Biofire data cited by Your Local Epidemiologist. Health professionals note that rest and fluids really do help boost your immune system.
Pemgarda Monoclonal Antibody Option for Immunocompromised Patients
For individuals with weakened immune systems who may not respond well to a Covid-19 vaccine—such as a dad who got a kidney transplant and takes anti-rejection drugs—monoclonal antibody treatments offer another option. According to Your Local Epidemiologist, Pemgarda is a monoclonal antibody specifically designed for people with weakened immune systems that delivers antibodies directly for bodies that can’t reliably build them themselves. Results from the placebo-controlled CANOPY Trial showed 94% and 84% efficacy at 3 and 6 months, respectively, working as well (or even better) than vaccines to actually stop infection, too. The treatment is an IV, two times 90 days apart, and exhibits low side effects.
Measles Data Disputes and CDC Reporting Scrutiny
Public health reporting faced unusual disruption over the weekend as the Centers for Disease Control and Prevention delayed and modified its online measles death statistics. According to Your Local Epidemiologist, the CDC website shifted between 0 measles deaths to 2, then to 0, then to an asterisk during real-time deliberations over child deaths in Pennsylvania. While the Health Department in Pennsylvania (as well as the coroner, the parents, and the midwife) says the child deaths last week were associated with measles, RFK Jr. says they aren’t. Because data is decentralized in the United States, flowing from local communities to states to the feds, withholding the data signals that CDC is choosing not to trust the states’ account, which is an unprecedented move.
Did You Know?
Monoclonal antibodies like Pemgarda bypass the body’s native immune response by delivering laboratory-engineered antibodies directly into the patient, providing rapid defense for individuals who cannot safely build their own immunity through traditional vaccination.
Frequently Asked Questions
When will the updated COVID-19 vaccines be available?
According to Your Local Epidemiologist, the updated Covid-19 vaccine should be available in the next two weeks.
What is Pemgarda and who is it for?
Pemgarda is a monoclonal antibody specifically designed for people with weakened immune systems.
How effective is Pemgarda against infection?
According to data from the CANOPY Trial cited by Your Local Epidemiologist, Pemgarda had a 94% and 84% efficacy at 3 and 6 months, respectively.
Why did the CDC change its measles death data?
Typically, measles data is updated on the CDC website on Fridays, but that update didn’t come last Friday, and then on Sunday the CDC updated the death data on the website in real time amid differing opinions between feds and everyone else.
If you found this public health update helpful, subscribe to our newsletter for evidence-based breakdowns of the latest medical science, and share this information with anyone who may benefit from learning about fall vaccine timing or specialized protection for immunocompromised family members.
Worth a look